Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
843 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 100 | Gilead SciencesINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT07114367 | NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma(POTENTIAL-M) | recruiting | Phase 1 | 9 | NOBO MedicineINDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06704945 | No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy(Neo-NAUTILUS) | recruiting | Phase 3 | 464 | Seoul National University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06921837 | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer | recruiting | Phase 1 / Phase 2 | 122 | Bolt Biotherapeutics, Inc.INDUSTRY | 3 | Jan 27, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT04373564 | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years(ODYSSEY) | recruiting | Phase 4 | 2,076 | GuerbetINDUSTRY | 8 | Jan 22, 2026 | clinicaltrials |
| NCT07143812 | A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 | 10 | CHA UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05620628 | Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | recruiting | Phase 2 | 25 | Jeeyun LeeOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06752096 | Robot-Assisted Neurovascular Intervention | recruiting | N/A | 10 | Navigantis Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07235007 | Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma(BRAVE) | recruiting | N/A | 120 | Aichi Medical UniversityOTHER | 2 | Jan 13, 2026 | clinicaltrials |
| NCT06163430 | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)(CARDINAL) | recruiting | Phase 1 / Phase 2 | 180 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 9 | Jan 12, 2026 | clinicaltrials |
| NCT05405595 | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 186 | Adagene IncINDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT07314073 | [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer | recruiting | Phase 2 | 85 | Asan Medical CenterOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06366789 | Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 150 | Lomond Therapeutics Holdings, Inc.INDUSTRY | 4 | Dec 31, 2025 | clinicaltrials |
| NCT07073365 | Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)(BOOST) | recruiting | Phase 2 | 70 | Pusan National University HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06828380 | A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion(IOPT) | recruiting | Phase 2 | 128 | National Cancer Center, KoreaOTHER_GOV | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06392477 | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 96 | SanofiINDUSTRY | 5 | Dec 23, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT06478693 | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | recruiting | Phase 1 | 70 | Myeloid TherapeuticsINDUSTRY | 3 | Dec 18, 2025 | clinicaltrials |
| NCT06724016 | Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 292 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 2 | Dec 17, 2025 | clinicaltrials |
| NCT07062627 | Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma | recruiting | Phase 2 | 12 | Hyungwoo ChoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06085755 | Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 61 | Jeeyun LeeOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06465433 | Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab | recruiting | Phase 2 | 25 | Incyte CorporationINDUSTRY | 5 | Dec 10, 2025 | clinicaltrials |
| NCT07269626 | PULSAR in Systemic Therapy for Pancreatic Cancer | recruiting | Phase 2 | 47 | Samsung Medical CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | recruiting | Phase 1 | 56 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT07014319 | Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies(MALMBA) | recruiting | Phase 2 | 20 | Seoul National University HospitalOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07263178 | A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer. | recruiting | — | 1,000 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05533983 | FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy(NIVO-FMT) | recruiting | N/A | 50 | Asan Medical CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT06920251 | Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy(OPTIMUS-EL) | recruiting | Phase 2 | 40 | Seoul National University HospitalOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07257523 | Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer | recruiting | Phase 2 | 33 | Yonsei UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05146778 | A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia(RELIEF) | recruiting | N/A | 230 | Gangnam Severance HospitalOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06544629 | Imjudo & Imfinzi PMS | recruiting | — | 246 | AstraZenecaINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05522868 | SB17170 Phase 1 Clinical Trial in Solid Tumors | recruiting | Phase 1 | 50 | SPARK BiopharmaINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05530057 | Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer(ESPERO) | recruiting | Phase 2 | 180 | Seoul National University HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07149090 | Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites | recruiting | Phase 1 / Phase 2 | 61 | Asan Medical CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06590961 | UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies | recruiting | Phase 1 | 94 | Ubix Therapeutics, Inc.INDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT07123415 | A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 110 | Aptabio Therapeutics, Inc.INDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05490433 | Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction(ROM) | recruiting | N/A | 790 | Yonsei UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07225374 | Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC | recruiting | Phase 2 | 48 | Samsung Medical CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06174987 | A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) | recruiting | Phase 3 | 50 | Daiichi SankyoINDUSTRY | 12 | Oct 15, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT07211139 | Head and Neck Advanced Research for Multi-Omics and Optimized Immunotherapy(HARMONI) | recruiting | — | 30 | Samsung Medical CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05377034 | Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients(STRATUM) | recruiting | Phase 2 | 100 | National Cancer Centre, SingaporeOTHER | 4 | Oct 6, 2025 | clinicaltrials |
| NCT06126666 | A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 96 | ABL Bio, Inc.INDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07190573 | Head and Neck Cancer Omics/Integrated Precision Medicine (HOPE)(HOPE) | recruiting | — | 350 | Samsung Medical CenterOTHER | 1 | Sep 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials